U-Neuron BiomedicalROCO:6973 12 Altman Z2-Score is 18.73 as of Jul. 12, 2026, which is 3% above its 10-year median of 18.17. GuruFocus rates ROCO:6973 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,392 Biotechnology companies, U-Neuron Biomedical ranks better than 92.6% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
U-Neuron Biomedical has a Altman Z2-Score of 18.73, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for U-Neuron Biomedical's Altman Z2-Score or its related term are showing as below:
ROCO:6973'
s Altman Z2-Score Range Over the Past 10 Years
Min: 10.46 Med: 18.17 Max: 29.18
Current: 18.73
During the past 6 years, U-Neuron Biomedical's highest Altman Z2-Score was 29.18. The lowest was 10.46. And the median was 18.17.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
U-Neuron Biomedical Altman Z2-Score Related Terms
U-Neuron Biomedical Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for U-Neuron Biomedical's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6973 vs VRTX, REGN, ALNY: Altman Z2-Score Comparison
For the Biotechnology subindustry, U-Neuron Biomedical's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
U-Neuron Biomedical Altman Z2-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where U-Neuron Biomedical's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
U-Neuron Biomedical's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.793
+
3.26
*
-0.0724
+
6.72
*
-0.0716
+
1.05
*
13.5653
=
18.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
U-Neuron Biomedical (ROCO:6973) has a Altman Z2-Score of 18.73 as of Jul. 12, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on U-Neuron Biomedical and its competitors. This is near median its historical median of 18.17. Over the past decade, U-Neuron Biomedical's Altman Z2-Score has ranged from 10.46 to 29.18. According to the industry distribution chart, U-Neuron Biomedical ranks #103 out of 1392 companies in the Biotechnology industry, placing it in the top 7.4%.
Is U-Neuron Biomedical's Altman Z2-Score too high?
U-Neuron Biomedical's current Altman Z2-Score of 18.73 is near median its 10-year median of 18.17. Over the past 10 years, this metric has ranged from a low of 10.46 to a high of 29.18. Based on the distribution chart, U-Neuron Biomedical ranks #103 out of 1392 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, U-Neuron Biomedical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, U-Neuron Biomedical ranks #103 out of 1392 companies for Altman Z2-Score. This places U-Neuron Biomedical in the top 7% of its industry — outperforming the majority of peers. Historically, U-Neuron Biomedical's own Altman Z2-Score has ranged from 10.46 to 29.18 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on U-Neuron Biomedical and its competitors. U-Neuron Biomedical's current Altman Z2-Score is 18.73, which is near median its own 10-year median of 18.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
U-Neuron Biomedical (ROCO:6973) has a current Altman Z2-Score of 18.73. The current Altman Z2-Score is 18.73, which is near median its 10-year median of 18.17. U-Neuron Biomedical's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current Altman Z2-Score is 18.73 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
12GF Score
Get the complete analysis for ROCO:6973
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6973 has been successfully added to your 
